Vadim Koshkin, MD
Associate Professor
Medicine
School of Medicine

I am a genitourinary medical oncologist and in this capacity I specialize in caring for patients with bladder, prostate, kidney and testicular cancers. My focus is in clinical and translational research in bladder and prostate cancers, in particular the design and implementation of clinical trials for patients with these malignancies and the discovery and validation of novel biomarkers and treatment targets.

Awards

Show all (14) Hide

• NIH Loan Repayment Program (LRP) Grant from National Cancer Institute, National Cancer Institute, 2020
• Prostate Cancer Foundation Young Investigator Award, Prostate Cancer Foundation, 2020
• Junior Clinical Investigator Award, Helen Diller Family Comprehensive Cancer Center, 2019
• John Quale Travel Fellowship Award, BCAN Bladder Cancer Think Tank, Bladder Cancer Advocacy Network, 2017
• Conquer Cancer Foundation Merit Award, ASCO 2017 Annual Meeting, Conquer Cancer Foundation, 2017
• Young Investigator Abstract Award, International Kidney Cancer Symposium, Kidney Cancer Association, 2017
• AACR/ASCO Methods in Clinical Cancer Research Workshop Participant, AACR/ASCO, 2016
• Conquer Cancer Foundation Merit Award, ASCO 2015 Annual Meeting, Conquer Cancer Foundation, 2015
• University of Michigan Health System, Making a Difference Award, University of Michigan Health System, 2013
• Keith Edson Scholarship for International Medicine Experience in West Africa, University of Chicago, Pritzker School of Medicine, 2012
• Teaching Assistant for Clinical Pathophysiology and Therapeutics (Awarded to the top 20% of medical school class), University of Chicago, Pritzker School of Medicine, 2012
• Certificate of Merit Award: Education Exhibit at 2009 RSNA Meeting, Radiological Society of North America, 2009
• Best Senior Thesis in Cognitive Science, University of Pennsylvania College Alumni Society Award, University of Pennsylvania, 2007
• George M. Pullman Foundation Academic Scholarship, George M. Pullman Foundation, 2003

Education & Training

Show all (4) Hide

• Hematology/Oncology Fellowship Cleveland Clinic 06/2018
• Internal Medicine Residency University of Michigan 06/2015
• MD Medicine University of Chicago, Pritzker School of Medicine 06/2012
• BA Cognitive Science University of Pennsylvania 05/2007

Websites

Show all (1) Hide

• Posts on X koshkin85 (X.com)

Grants and Projects

Show all (1) Hide

• Using CDK 4/6 Inhibition to Augment PSMA Expression in Advanced Prostate Cancer and Enhance Clinical Responses to PSMA-Targeted Radioligand Therapy, Prostate Cancer Foundation, 2021-2024

Publications (113)

Top publication keywords:
PPAR gammaCisplatinGene AmplificationNeoadjuvant TherapyProstatic Neoplasms, Castration-ResistantAntibodies, MonoclonalUrotheliumUrinary Bladder NeoplasmsGATA3 Transcription FactorAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalUrologic NeoplasmsImmunoconjugatesCarcinoma, Transitional CellReceptor, ErbB-2

• Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study.
  European urology 2025 Jindal T, Jiang CY, Alhalabi O, Nguyen CB, Oh E, Tsung I, Bakaloudi DR, Talukder R, Davidsohn M, Freeman D, Epstein IY, Ding CC, Nizam A, Glover MJ, Khaki AR, Taylor AK, Lemke E, Jang A, Evans ST, …
• Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data.
  European urology oncology 2024 Jindal T, Jiang C, Alhalabi O, Nizam A, Nguyen C, Talukder R, Bakaloudi D, Davidsohn M, Freeman D, Glover M, Khaki AR, Evans S, Lemke E, Bose R, Sim W, Pywell C, Basu A, Kilari D, Barata PC, Bilen MA,…
• Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.
  Cancer 2021 Koshkin VS, Henderson N, James M, Natesan D, Freeman D, Nizam A, Su CT, Khaki AR, Osterman CK, Glover MJ, Chiang R, Makrakis D, Talukder R, Lemke E, Olsen TA, Jain J, Jang A, Ali A, Jindal T, Chou J, …
• TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor.
  Journal for immunotherapy of cancer 2021 de Kouchkovsky I, Zhang L, Philip EJ, Wright F, Kim DM, Natesan D, Kwon D, Ho H, Ho S, Chan E, Porten SP, Wong AC, Desai A, Huang FW, Chou J, Oh DY, Pruthi RS, Fong L, Small EJ, Friedlander TW, …
• Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2018 Koshkin VS, Garcia JA, Reynolds J, Elson P, Magi-Galluzzi C, McKenney JK, Isse K, Bishop E, Saunders LR, Balyimez A, Rashid S, Hu M, Stephenson AJ, Fergany AF, Lee BH, Haber GP, Dowlati A, Gilligan T,…
• Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.
  Journal for immunotherapy of cancer 2018 Koshkin VS, Barata PC, Zhang T, George DJ, Atkins MB, Kelly WJ, Vogelzang NJ, Pal SK, Hsu J, Appleman LJ, Ornstein MC, Gilligan T, Grivas P, Garcia JA, Rini BI
• Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With Survival.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016 Koshkin VS, Bolejack V, Schwartz LH, Wahl RL, Chugh R, Reinke DK, Zhao B, O JH, Patel SR, Schuetze SM, Baker LH

Show all (106 more) Hide

• Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study.
  The oncologist 2025 Jiang CY, Hwang H, Epstein IY, Bakaloudi DR, Talukder R, Taylor AK, Nizam A, Jindal T, Glover MJ, Khaki AR, Barata PC, Nguyen CB, Oh E, Davis NB, Mabey H, Hoimes CJ, Evans ST, Abuqayas B, Lemke E, …
• Genomic alterations and associated outcomes in patients with PSMA-positive metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617.
  The oncologist 2025 Panian J, Henderson NC, Herchenhorn D, Barata PC, Bilen MA, Graham L, Heath E, Hwang C, Supernois A, Kilari D, Thapa B, Koshkin VS, Jindal T, Nauseef JT, Sokolova A, Amery T, Zakharia Y, Schweizer MT,…
• Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study.
  Urologic oncology 2025 Jindal T, Jiang CY, Alhalabi O, Davidsohn M, Freeman D, Epstein IY, Bakaloudi DR, Talukder R, Nizam A, Nguyen CB, Oh E, Tsung I, Glover MJ, Khaki AR, Taylor AK, Jaime-Casas S, Jang A, Lemke E, Pywell …
• Treatment-Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study.
  Cancer medicine 2025 Nizam A, Nguyen CB, Li J, Zabor EC, Msaouel P, Jiang CY, Alhalabi O, Oh E, Davidsohn MP, Epstein IB, Bakaloudi DR, Talukder R, Jindal T, Taylor AK, Glover MJ, Khaki AR, Lemke E, Mabey H, Abuqayas B, …
• Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer.
  Nature communications 2025 Chang K, Delavan HM, Yip E, Kasap C, Zhu J, Lodha R, Liao SY, Berman SC, Carretero-Gonzalez A, Basar M, Gokturk Ozcan G, Teo MY, Solit DB, Rosenberg JE, Al-Ahmadie H, Ding CCK, Chan E, Steri V, Porten…
• Advanced urothelial carcinoma treated with enfortumab vedotin and pembrolizumab: a path to cure?
  The oncologist 2025 Jang A, Tripathi N, Lanka SM, Kumar HLS, Jain P, Calaway A, Shoag JE, Vince R, Mendiratta P, Rao S, Garcia JA, Brown JR, Koshkin VS, Campbell MT, Singh P, Barata PC
• Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer.
  European urology 2025 St-Laurent MP, Singh P, McConkey DJ, Lucia MS, Koshkin VS, Stratton KL, Bivalacqua TJ, Kassouf W, Porten SP, Bangs R, Plets M, Thompson IM, Meeks JJ, Caruso VM, Ward CT, Mazzarella BC, Phillips KG, …
• Obesity's Disparate Impact on COVID-19 Outcomes in Asian American Patients with Cancer.
  medRxiv : the preprint server for health sciences 2025 Nguyen RH, Shah PK, Mishra S, Fu J, Reid S, Hawley JE, Hwang C, Singh SRK, Gatson NT, Florez N, Chism D, Serrano OK, Bashir B, Nagaraj G, Mckay RR, Hayes-Lattin B, Koshkin VS, Acoba JD, Zamulko O, …
• Testing and Interpretation of Human Epidermal Growth Factor Receptor 2 Protein Expression and ERBB2 Gene Amplification in Advanced Urothelial Carcinoma.
  JCO precision oncology 2025 Koshkin VS, Schafer JM, Scherrer E, Boyiddle C, Schwartz NRM, Yu H, Fang Q, Baker AF, Sayedian FH, Chan E
• Response and Survival With Immune Checkpoint Inhibitor in Patients With Advanced Urothelial Carcinoma and Histology Subtypes.
  Clinical genitourinary cancer 2025 Bakaloudi DR, Talukder R, Enright T, Leary JB, Makrakis D, Diamantopoulos LN, Hobeika C, Thomas VM, Swami U, Zakopoulou R, Bamias A, Brown JR, Pinato DJ, Latchford C, Jindal T, Koshkin VS, Murgic J, …
• Unmet Potential of Antibody-Drug Conjugates: An Evaluation of the Past, Present, and Future of Antibody-Drug Conjugate Development in Advanced Urothelial Carcinoma.
  American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2025 Zarrabi KK, Saxena A, Mouw KW, Koshkin VS, Friedlander T
• Pembrolizumab Retreatment in Patients with Advanced or Metastatic Urothelial Carcinoma Who Responded to First-course Pembrolizumab-based Therapy.
  European urology 2024 Koshkin VS, Danchaivijitr P, Bae WK, Semenov A, Ozyilkan O, Su YL, Arranz Arija JA, Tsujihata M, Bögemann M, Hendriks MP, Delgado SN, Rosenbaum E, Lopez KA, Bavle A, Liu CC, Imai K, Furka A
• Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma.
  Clinical genitourinary cancer 2024 Talukder R, Bakaloudi DR, Makrakis D, Diamantopoulos LN, Enright T, Leary JB, Raychaudhuri R, Tripathi N, Agarwal N, Jindal T, Brown JR, Zakharia Y, Rey-Cárdenas M, Castellano D, Nguyen CB, Alva A, …
• Expanding the Reach of FGFR Inhibitors to Advance Precision Medicine in Urothelial Carcinoma.
  European urology 2024 Koshkin VS, Sonpavde GP
• Patients Can Administer Mobile Audio Recordings to Increase Knowledge in Advanced Prostate Cancer.
  Cancer medicine 2024 Kwon DH, Trihy L, Darvish N, Hearst E, Sumra S, Borno HT, Bose R, Chou J, de Kouchkovsky I, Desai A, Ekstrand B, Friedlander T, Kaur G, Koshkin VS, Nesheiwat S, Sepucha K, Small EJ, Aggarwal RR, …
• Bempegaldesleukin plus nivolumab in first-line advanced/metastatic urothelial carcinoma: Results from a phase II single-arm study (PIVOT-10).
  Urologic oncology 2024 Siefker-Radtke AO, Huddart RA, Bilen MA, Balar A, Castellano D, Sridhar SS, De Giorgi U, Penkov K, Vasiliev A, Peer A, Järvinen R, Harputluoglu H, Koshkin VS, Poushnejad S, Wang T, Qureshi A, …
• Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint Inhibitor.
  Clinical genitourinary cancer 2024 Bakaloudi DR, Talukder R, Makrakis D, Diamantopoulos L, Enright T, Leary JB, Patgunarajah U, Thomas VM, Swami U, Agarwal N, Jindal T, Koshkin VS, Brown JR, Barata P, Murgic J, Miletic M, Johnson J, …
• HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gains.
  The oncologist 2024 Zhu X, Chan E, Turski ML, Mendez CE, Hsu SC, Kumar V, Shipp C, Jindal T, Chang K, Onodera C, Devine WP, Grenert JP, Stohr BA, Ding CC, Stachler MD, Quigley DA, Feng FY, Chu CE, Porten SP, Chou J, …
• DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes.
  JCO precision oncology 2024 Graham LS, Henderson NC, Kellezi O, Hwang C, Barata PC, Bilen MA, Kilari D, Pierro M, Thapa B, Tripathi A, Mo G, Labriola M, Park JJ, Rothstein S, Garje R, Koshkin VS, Patel VG, Dorff T, Armstrong AJ,…
• Clinical implications of Wnt pathway genetic alterations in men with advanced prostate cancer.
  Prostate cancer and prostatic diseases 2024 Broderick A, Pan E, Li J, Chu A, Hwang C, Barata PC, Cackowski FC, Labriola M, Ghose A, Bilen MA, Kilari D, Thapa B, Piero M, Graham L, Tripathi A, Garje R, Koshkin VS, Hernandez E, Dorff TB, …
• Comparison of 18F-DCFPyL and 68Ga-PSMA-11 for 177Lu-PSMA-617 therapy patient selection.
  Frontiers in oncology 2024 Yadav S, Kim ST, Tuchayi AM, Jiang F, Morley A, Saelee R, Wang Y, Juarez R, Lawnh-Heath C, Koshkin VS, Hope TA
• Correlation analyses of radiographic progression-free survival with clinical and health-related quality of life outcomes in metastatic castration-resistant prostate cancer: Analysis of the phase 3 VISION trial.
  Cancer 2024 Morris MJ, de Bono J, Nagarajah J, Sartor O, Wei XX, Nordquist LT, Koshkin VS, Chi KN, Krause BJ, Herrmann K, Rahbar K, Vickers A, Mirante O, Ghouse R, Fizazi K, Tagawa ST
• Therapies After Progression on Enfortumab Vedotin and Pembrolizumab: Navigating Second-line Options for Metastatic Urothelial Carcinoma in the New Treatment Landscape.
  European urology focus 2024 Brown JR, Koshkin VS
• Therapy Attrition and Lessons for Future Approaches to Treatment of Advanced Urothelial Cancer.
  JAMA network open 2024 Koshkin VS
• CRE24-034: Successful Management of Locally Advanced and Oligometastatic Urothelial Carcinoma With Pembrolizumab-Based Induction Regimen Followed by Consolidative Radical Resection of the Primary Tumor: A Multi-Institutional Case Series.
  Journal of the National Comprehensive Cancer Network : JNCCN 2024 Jang A, Jindal T, Calaway AC, Shoag JE, Koshkin VS, Barata PC
• Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable Alterations.
  JCO precision oncology 2024 Park JJ, Chu A, Li J, Ali A, McKay RR, Hwang C, Labriola MK, Jang A, Kilari D, Mo G, Ravindranathan D, Graham LS, Sokolova A, Tripathi A, Pilling A, Jindal T, Ravindra A, Cackowski FC, Sweeney PL, …
• Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration.
  Prostate cancer and prostatic diseases 2024 Zengin ZB, Henderson NC, Park JJ, Ali A, Nguyen C, Hwang C, Barata PC, Bilen MA, Graham L, Mo G, Kilari D, Tripathi A, Labriola M, Rothstein S, Garje R, Koshkin VS, Patel VG, Schweizer MT, Armstrong …
• Initial Experience with 68Ga-FAP-2286 PET Imaging in Patients with Urothelial Cancer.
  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2024 Koshkin VS, Kumar V, Kline B, Escobar D, Aslam M, Cooperberg MR, Aggarwal RR, de Kouchkovsky I, Chou J, Meng MV, Friedlander T, Porten S, Hope TA
• Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma.
  Cancer drug resistance (Alhambra, Calif.) 2023 Sweeney PL, Suri Y, Basu A, Koshkin VS, Desai A
• PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant Chemotherapy.
  European urology oncology 2023 Grivas P, Koshkin VS, Chu X, Cole S, Jain RK, Dreicer R, Cetnar JP, Sundi D, Gartrell BA, Galsky MD, Woo B, Li-Ning-Tapia E, Hahn NM, Carducci MA
• Enfortumab vedotin and pembrolizumab as new first-line standard for metastatic urothelial cancer.
  Med (New York, N.Y.) 2023 Zhu X, Koshkin VS
• Central Nervous System Disease Progression Among Patients With Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin: A Case Series.
  Clinical genitourinary cancer 2023 Shipp C, Jindal T, Chou J, Friedlander TW, Koshkin VS, Kumar V
• Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial.
  The Lancet. Oncology 2023 Aggarwal R, Starzinski S, de Kouchkovsky I, Koshkin V, Bose R, Chou J, Desai A, Kwon D, Kaushal S, Trihy L, Rastogi M, Ippisch R, Aslam M, Friedlander T, Feng F, Oh D, Cheung A, Small E, Evans M, Fong…
• Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study.
  eLife 2023 Nagaraj G, Vinayak S, Khaki AR, Sun T, Kuderer NM, Aboulafia DM, Acoba JD, Awosika J, Bakouny Z, Balmaceda NB, Bao T, Bashir B, Berg S, Bilen MA, Bindal P, Blau S, Bodin BE, Borno HT, Castellano C, …
• Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19.
  JAMA oncology 2023 Gulati S, Hsu CY, Shah S, Shah PK, Zon R, Alsamarai S, Awosika J, El-Bakouny Z, Bashir B, Beeghly A, Berg S, de-la-Rosa-Martinez D, Doroshow DB, Egan PC, Fein J, Flora DB, Friese CR, Fromowitz A, …
• Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer.
  JAMA network open 2023 Hwang C, Henderson NC, Chu SC, Holland B, Cackowski FC, Pilling A, Jang A, Rothstein S, Labriola M, Park JJ, Ghose A, Bilen MA, Mustafa S, Kilari D, Pierro MJ, Thapa B, Tripathi A, Garje R, Ravindra A…
• Editorial: Methods in genitourinary oncology.
  Frontiers in oncology 2023 Jang A, Sella A, Nassar AH, Koshkin VS
• Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605.
  European urology 2023 Black PC, Tangen CM, Singh P, McConkey DJ, Lucia MS, Lowrance WT, Koshkin VS, Stratton KL, Bivalacqua TJ, Kassouf W, Porten SP, Bangs R, Plets M, Thompson IM, Lerner SP
• Clinical implications of AR alterations in advanced prostate cancer: A multi-institutional collaboration.
  Research square 2023 Dorff T, Zengin Z, Henderson N, Ali A, Nguyen C, Hwang C, Barata PC, Bilen M, Graham L, Mo G, Kilari D, Tripathi A, Labriola M, Rothstein S, Garje R, Koshkin V, Patel V, Schweizer M, Armstrong A, …
• Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer.
  Current treatment options in oncology 2023 Singh A, Osbourne AS, Koshkin VS
• Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" Experience.
  Clinical genitourinary cancer 2023 Bakaloudi DR, Talukder R, Lin GI, Makrakis D, Diamantopoulos LN, Tripathi N, Agarwal N, Zakopoulou R, Bamias A, Brown JR, Pinato DJ, Korolewicz J, Jindal T, Koshkin VS, Murgic J, Miletic M, Frobe A, …
• COVID-19 severity and cardiovascular outcomes in SARS-CoV-2-infected patients with cancer and cardiovascular disease.
  Translational oncology 2023 Moey MYY, Hennessy C, French B, Warner JL, Tucker MD, Hausrath DJ, Shah DP, DeCara JM, Bakouny Z, Labaki C, Choueiri TK, Dent S, Akhter N, Ismail-Khan R, Tachiki L, Slosky D, Polonsky TS, Awosika JA, …
• Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial.
  The Lancet. Oncology 2023 Fizazi K, Herrmann K, Krause BJ, Rahbar K, Chi KN, Morris MJ, Sartor O, Tagawa ST, Kendi AT, Vogelzang N, Calais J, Nagarajah J, Wei XX, Koshkin VS, Beauregard JM, Chang B, Ghouse R, DeSilvio M, …
• Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin.
  Clinical genitourinary cancer 2023 Jindal T, Zhang L, Deshmukh P, Reyes K, Chan E, Kumar V, Zhu X, Maldonado E, Feng S, Johnson M, Angelidakis A, Kwon D, Desai A, Borno HT, Bose R, Wong A, Hong J, Carroll P, Meng M, Porten S, Aggarwal …
• Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer.
  Frontiers in oncology 2023 Jindal T, Zhu X, Bose R, Kumar V, Maldonado E, Deshmukh P, Shipp C, Feng S, Johnson MS, Angelidakis A, Kwon D, Borno HT, de Kouchkovsky I, Desai A, Aggarwal R, Fong L, Small EJ, Wong A, Porten S, Chou…
• Clinical Characteristics, Racial Inequities, and Outcomes in Patients with Breast Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Cohort Study.
  medRxiv : the preprint server for health sciences 2023 Nagaraj G, Vinayak S, Khaki AR, Sun T, Kuderer NM, Aboulafia DM, Acoba JD, Awosika J, Bakouny Z, Balmaceda NB, Bao T, Bashir B, Berg S, Bilen MA, Bindal P, Blau S, Bodin BE, Borno HT, Castellano C, …
• Laryngeal Mucous Membrane Pemphigoid as an Immune-related Adverse Effect of Pembrolizumab Treatment.
  Journal of voice : official journal of the Voice Foundation 2023 Lagos-Villaseca A, Koshkin VS, Kinet MJ, Rosen CA
• Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19.
  JAMA oncology 2023 Bakouny Z, Labaki C, Grover P, Awosika J, Gulati S, Hsu CY, Alimohamed SI, Bashir B, Berg S, Bilen MA, Bowles D, Castellano C, Desai A, Elkrief A, Eton OE, Fecher LA, Flora D, Galsky MD, Gatti-Mays ME…
• Editorial: Radical cystectomy in bladder cancer patients.
  Frontiers in oncology 2022 Koshkin VS, Almassi N, Aragon-Ching JB
• Quality of life for men with metastatic castrate-resistant prostate cancer participating in an aerobic and resistance exercise pilot intervention.
  Urologic oncology 2022 Langlais CS, Chen YH, Van Blarigan EL, Chan JM, Ryan CJ, Zhang L, Borno HT, Newton RU, Luke A, Bang AS, Panchal N, Tenggara I, Schultz B, Lavaki E, Pinto N, Aggarwal R, Friedlander T, Koshkin VS, …
• Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers.
  Urologic oncology 2022 Kwon DH, Shakhnazaryan N, Shui D, Hong JC, Mohamad O, de Kouchkovsky I, Borno HT, Bose R, Chou J, Desai A, Fong L, Friedlander TW, Koshkin VS, Aggarwal RR, Feng FY, Hope TA, Small EJ
• Treatment Rechallenge With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma.
  Clinical genitourinary cancer 2022 Makrakis D, Bakaloudi DR, Talukder R, Lin GI, Diamantopoulos LN, Jindal T, Vather-Wu N, Zakharia Y, Tripathi N, Agarwal N, Dawsey S, Gupta S, Lu E, Drakaki A, Liu S, Zakopoulou R, Bamias A, Fulgenzi …
• Assessing Unique Risk Factors for COVID-19 Complications Among Cancer Patients: A Multi-ethnic Cohort Study.
  Journal of immigrant and minority health 2022 Borno HT, Kim MO, Tolstykh I, Lin A, Hong JC, Yousefi S, Zhang S, McKay RR, Harismendy O, Razavi P, Cinar P, Rugo H, Koshkin VS, Rabow M, Wang C, Bailey A, Small EJ
• HER2 expression in urothelial carcinoma, a systematic literature review.
  Frontiers in oncology 2022 Scherrer E, Kang A, Bloudek LM, Koshkin VS
• Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma.
  Clinical genitourinary cancer 2022 Talukder R, Makrakis D, Lin GI, Diamantopoulos LN, Dawsey S, Gupta S, Carril-Ajuria L, Castellano D, de Kouchkovsky I, Jindal T, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Tripathi N…
• Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma.
  Clinical genitourinary cancer 2022 Makrakis D, Talukder R, Lin GI, Diamantopoulos LN, Dawsey S, Gupta S, Carril-Ajuria L, Castellano D, de Kouchkovsky I, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Tripathi N, Agarwal …
• Making National Cancer Institute-Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study.
  JMIR cancer 2022 Kalra M, Henry E, McCann K, Karuturi MS, Bustamante Alvarez JG, Parkes A, Wesolowski R, Wei M, Mougalian SS, Durm G, Qin A, Schonewolf C, Trivedi M, Armaghani AJ, Wilson FH, Iams WT, Turk AA, Vikas P,…
• COVID-19 Outcomes Among Patients With Cancer: Observations From the University of California Cancer Consortium COVID-19 Project Outcomes Registry.
  The oncologist 2022 Borno HT, Kim MO, Hong JC, Yousefi S, Lin A, Tolstykh I, Zhang S, McKay RR, Harismendy O, Cinar P, Rugo H, Koshkin VS, Rabow M, Wang C, Bailey A, Small EJ
• Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19.
  Blood cancer discovery 2022 Rubinstein SM, Bhutani D, Lynch RC, Hsu CY, Shyr Y, Advani S, Mesa RA, Mishra S, Mundt DP, Shah DP, Sica RA, Stockerl-Goldstein KE, Stratton C, Weiss M, Beeghly-Fadiel A, Accordino M, Assouline SE, …
• Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate Cancer.
  The oncologist 2022 Freeman MN, Jang A, Zhu J, Sanati F, Nandagopal L, Ravindranathan D, Desai A, Phone A, Nussenzveig R, Jaeger E, Caputo SA, Koshkin VS, Swami U, Basu A, Bilen MA, Agarwal N, Sartor O, Burgess EF, …
• APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer.
  Frontiers in oncology 2022 Natesan D, Zhang L, Martell HJ, Jindal T, Devine P, Stohr B, Espinosa-Mendez C, Grenert J, Van Ziffle J, Joseph N, Umetsu S, Onodera C, Turski M, Chan E, Desai A, Aggarwal R, Wong A, Porten S, Chou J,…
• TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells.
  European urology oncology 2022 Chou J, Trepka K, Sjöström M, Egusa EA, Chu CE, Zhu J, Chan E, Gibb EA, Badura ML, Contreras-Sanz A, Stohr BA, Meng MV, Pruthi RS, Lotan Y, Black PC, Porten SP, Koshkin VS, Friedlander TW, Feng FY
• Coinfections in Patients With Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Study.
  Open forum infectious diseases 2022 Satyanarayana G, Enriquez KT, Sun T, Klein EJ, Abidi M, Advani SM, Awosika J, Bakouny Z, Bashir B, Berg S, Bernardes M, Egan PC, Elkrief A, Feldman LE, Friese CR, Goel S, Gomez CG, Grant KL, Griffiths…
• Mobile Audio Recording Technology to Promote Informed Decision Making in Advanced Prostate Cancer.
  JCO oncology practice 2021 Kwon DH, Karthikeyan S, Chang A, Borno HT, Koshkin VS, Desai A, Bose R, Friedlander T, Rodvelt T, Li P, Small EJ, Aggarwal RR, Belkora J
• Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin.
  Clinical genitourinary cancer 2021 Talukder R, Makrakis D, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Santos VS, Agarwal N, Jain J, Zakharia Y, …
• Repeat Treatment of Patients With Advanced Urothelial Carcinoma With Immune Checkpoint Inhibitors Following Prior Progression on a Checkpoint Inhibitor Regimen: A Case Series.
  Clinical genitourinary cancer 2021 Jindal T, Chou J, Friedlander T, Barata PC, Koshkin VS
• Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer.
  BJU international 2021 Makrakis D, Talukder R, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Santos VS, Agarwal N, Jain J, Zakharia Y, …
• Feasibility, safety, and acceptability of a remotely monitored exercise pilot CHAMP: A Clinical trial of High-intensity Aerobic and resistance exercise for Metastatic castrate-resistant Prostate cancer.
  Cancer medicine 2021 Kenfield SA, Van Blarigan EL, Panchal N, Bang A, Zhang L, Graff RE, Chen YH, Ryan CJ, Luke A, Newton RU, Tenggara I, Schultz B, Wang E, Lavaki E, Zuniga K, Pinto N, Borno H, Aggarwal R, Friedlander T,…
• Treatment options for advanced urothelial cancer after progression on chemotherapy and immune checkpoint inhibitors: a literature review.
  Translational andrology and urology 2021 Koshkin VS, Osbourne AS, Grivas P
• PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer.
  Prostate cancer and prostatic diseases 2021 Koshkin VS, Patel VG, Ali A, Bilen MA, Ravindranathan D, Park JJ, Kellezi O, Cieslik M, Shaya J, Cabal A, Brown L, Labriola M, Graham LS, Pritchard C, Tripathi A, Nusrat S, Barata P, Jang A, Chen SR, …
• Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19.
  JAMA oncology 2021 Thompson MA, Henderson JP, Shah PK, Rubinstein SM, Joyner MJ, Choueiri TK, Flora DB, Griffiths EA, Gulati AP, Hwang C, Koshkin VS, Papadopoulos EB, Robilotti EV, Su CT, Wulff-Burchfield EM, Xie Z, Yu …
• Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2021 Chu CE, Sjöström M, Egusa EA, Gibb EA, Badura ML, Zhu J, Koshkin VS, Stohr BA, Meng MV, Pruthi RS, Friedlander TW, Lotan Y, Black PC, Porten SP, Feng FY, Chou J
• Reply to R. Kebudi et al.
  JCO oncology practice 2021 Tsu-Yu Wu J, Kwon DH, Glover M, Henry S, Wood D, Rubin D, Koshkin V, Schapira L, Shah SA
• PD-L1 Expression and Treatment Implications in Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review
  Kidney Cancer 2021 Jang A, Sweeney PL, Barata PC, Koshkin VS.
• Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium.
  Annals of oncology : official journal of the European Society for Medical Oncology 2021 Grivas P, Khaki AR, Wise-Draper TM, French B, Hennessy C, Hsu CY, Shyr Y, Li X, Choueiri TK, Painter CA, Peters S, Rini BI, Thompson MA, Mishra S, Rivera DR, Acoba JD, Abidi MZ, Bakouny Z, Bashir B, …
• Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer.
  Cancer 2021 Kwon DH, Chou J, Yip SM, Reimers MA, Zhang L, Wright F, Dhawan MS, Borno HT, Desai A, Aggarwal RR, Wyatt AW, Small EJ, Alva AS, Chi KN, Feng FY, Koshkin VS
• Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes.
  BJU international 2021 Esagian SM, Khaki AR, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Santos VS, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, …
• Update on First-Line Combination Treatment Approaches in Metastatic Clear-Cell Renal Cell Carcinoma.
  Current treatment options in oncology 2021 Christensen BR, Hajja YM, Koshkin V, Barata PC
• A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors.
  European urology oncology 2021 Khaki AR, Li A, Diamantopoulos LN, Miller NJ, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Koshkin V, Park J, Alva A, Bilen MA, Stewart T, Santos V, Agarwal N, Jain J, Zakharia Y, Morales-Barrera …
• Changes in Cancer Management due to COVID-19 Illness in Patients with Cancer in Northern California.
  JCO oncology practice 2020 Wu JT, Kwon DH, Glover MJ, Henry S, Wood D, Rubin DL, Koshkin VS, Schapira L, Shah SA
• Evaluating determinants of receipt of molecular imaging in biochemical recurrent prostate cancer.
  Cancer medicine 2020 Borno HT, Kuo Lin T, Odisho AY, Desai A, Koshkin V, Werner K, Legaspi N, Bucknor M, Bell A, Zhang S, Hope TA
• Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort.
  Frontiers in oncology 2020 Barata P, Hatton W, Desai A, Koshkin V, Jaeger E, Manogue C, Cotogno P, Light M, Lewis B, Layton J, Sartor O, Basu A, Kilari D, Emamekhoo H, Bilen MA
• PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer.
  Future oncology (London, England) 2020 Huddart RA, Siefker-Radtke AO, Balar AV, Bilen MA, Powles T, Bamias A, Castellano D, Khalil MF, Van Der Heijden MS, Koshkin VS, Pook DW, Özgüroglu M, Santiago L, Zhong B, Chien D, Lin W, Tagliaferri …
• Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma.
  The Journal of urology 2020 Wei XX, Werner L, Teo MY, Rosenberg JE, Koshkin VS, Grivas P, Szabados B, Morrison L, Powles T, Carril-Ajuria L, Castellano D, Velho PI, Hahn NM, McKay RR, Raggi D, Necchi A, Kanesvaran R, Alerasool P…
• Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
  Lancet (London, England) 2020 Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, Shete S, Hsu CY, Desai A, de Lima Lopes G, Grivas P, Painter CA, Peters S, Thompson MA, Bakouny Z, Batist G, Bekaii-Saab T, Bilen MA…
• Randomized phase II trial of neoadjuvant everolimus in patients with high-risk localized prostate cancer.
  Investigational new drugs 2019 Koshkin VS, Mir MC, Barata P, Gul A, Gupta R, Stephenson AJ, Kaouk J, Berglund R, Magi-Galluzzi C, Klein EA, Dreicer R, Garcia JA
• The role of avelumab in advanced urothelial carcinoma in the context of a dynamic treatment landscape.
  Translational cancer research 2019 Koshkin VS, Basu A, Grivas P
• Systematic Review: Targeting HER2 in Bladder Cancer
  Bladder Cancer 2019 Koshkin VS, O’Donnell P, Yu EY, Grivas P
• Translational Cancer Research
  The role of avelumab in advanced urothelial carcinoma in the context of a dynamic treatment landscape 2018 Koshkin VS, Basu A, Grivas P
• Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials.
  Therapeutic advances in urology 2018 Koshkin VS, Small EJ
• Effect of Switching Systemic Treatment After Stereotactic Radiosurgery for Oligoprogressive, Metastatic Renal Cell Carcinoma.
  Clinical genitourinary cancer 2018 Barata PC, Mendiratta P, Kotecha R, Gopalakrishnan D, Juloori A, Chao ST, Koshkin V, Ornstein M, Gilligan TD, Wood LS, Rini BI, Angelov L, Garcia JA
• HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer.
  The Journal of clinical investigation 2018 Alyamani M, Emamekhoo H, Park S, Taylor J, Almassi N, Upadhyay S, Tyler A, Berk MP, Hu B, Hwang TH, Figg WD, Peer CJ, Chien C, Koshkin VS, Mendiratta P, Grivas P, Rini B, Garcia J, Auchus RJ, Sharifi …
• Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.
  The Prostate 2018 Barata P, Emamekhoo H, Mendiratta P, Koshkin V, Tyler A, Ornstein M, Rini BI, Gilligan T, Kyriakopoulos C, Garcia JA
• Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook.
  Therapeutics and clinical risk management 2018 Gopalakrishnan D, Koshkin VS, Ornstein MC, Papatsoris A, Grivas P
• Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies.
  Targeted oncology 2018 Barata PC, Gopalakrishnan D, Koshkin VS, Mendiratta P, Karafa M, Allman K, Martin A, Beach J, Profusek P, Tyler A, Wood L, Ornstein M, Gilligan T, Rini BI, Garcia JA, Grivas P
• Perioperative chemotherapy for muscle-invasive bladder cancer: the importance of multidisciplinary management for evidence-based practice and transformative research.
  Translational andrology and urology 2018 Koshkin VS, Grivas P
• Targeted Oncology
  Future Directions of Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer 2018 Koshkin VS, Grivas P
• Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma.
  Current oncology reports 2018 Koshkin VS, Grivas P
• Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function.
  Clinical genitourinary cancer 2018 Koshkin VS, Barata PC, Rybicki LA, Zahoor H, Almassi N, Redden AM, Fergany AF, Kaouk J, Haber GP, Stephenson AJ, Ornstein MC, Gilligan T, Garcia JA, Rini BI, Grivas P
• Patient Characteristics, Treatment Patterns and Prognostic Factors in Squamous Cell Bladder Cancer.
  Clinical genitourinary cancer 2017 Zahoor H, Elson P, Stephenson A, Haber GP, Kaouk J, Fergany A, Lee B, Koshkin V, Ornstein M, Gilligan T, Garcia JA, Rini B, Grivas P
• Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance.
  Annals of oncology : official journal of the European Society for Medical Oncology 2017 Barata PC, Koshkin VS, Funchain P, Sohal D, Pritchard A, Klek S, Adamowicz T, Gopalakrishnan D, Garcia J, Rini B, Grivas P
• Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis.
  European urology focus 2017 Necchi A, Mariani L, Lo Vullo S, Yu EY, Woods ME, Wong YN, Harshman LC, Alva A, Sternberg CN, Bamias A, Grivas P, Koshkin VS, Roghmann F, Dobruch J, Eigl BJ, Nappi L, Milowsky MI, Niegisch G, Pal SK, …
• Cancer vaccines at the age of immune checkpoint inhibitors: reasonable approach as combination therapy in advanced urothelial carcinoma?
  Annals of oncology : official journal of the European Society for Medical Oncology 2017 Grivas P, Koshkin VS, Pal SK
• Emerging therapeutics in refractory renal cell carcinoma.
  Expert opinion on pharmacotherapy 2016 Koshkin VS, Rini BI
• CAD-associated reader error in CT colonography.
  Academic radiology 2012 Koshkin VS, Hinshaw JL, Wroblewski K, Dachman AH
• Caspase-mediated cell death predominates following engraftment of neural progenitor cells into traumatically injured rat brain.
  Brain research 2005 Bakshi A, Keck CA, Koshkin VS, LeBold DG, Siman R, Snyder EY, McIntosh TK